相关实验视频
Updated: Sep 11, 2025

10:17
The Tail Suspension Test
Published on: January 28, 2012
80.9K
在患有格雷夫斯病的患者中,疗法的安全性和有效性
Ümit Çavdar1, Özlem Eren1, Serkan Karaıslı2
1Division of Endocrinology and Metabolism, Atatürk Training and Research Hospital, Katip Çelebi University, Izmir, Turkey.
Clinical endocrinology
|August 19, 2025
概括
当抗甲状腺药物失败时,有效控制甲状腺功能障碍症,显示出快速的生物化学改善. 由于潜在的副作用,仔细监测和变化是必不可少的.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 是甲状腺功能增强症的辅助疗法,当常规治疗是禁忌的.
- 格雷夫斯病是甲状腺功能障碍的常见原因,需要有效的管理策略.
研究的目的:
- 评估在患有格雷夫斯病的患者中的疗效和安全性.
- 评估作为甲状腺功能增强症的桥梁疗法的作用.
主要方法:
- 对14名格雷夫斯病患者的回顾性观察性研究,不耐受胺胺.
- 在治疗前后分析甲状腺激素,标记物和电解质.
- 使用配对样本t测试和线性混合效应模型进行统计分析.
主要成果:
- 显著降低了自由T4和自由T3水平.
- 尿密度的下降表明了潜在的早期管状脏效应.
- 没有观察到血清,或肌素的显著变化;高血症没有显著变化.
结论:
- 提供了快速的甲状腺功能增高的生化控制.
- 对于不能耐受抗甲状腺治疗的患者来说,它是一种有价值的选择.
- 建议对脏和代谢障碍进行警监测.
相关概念视频
Mania and Antimanic Drugs: Overview
319
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
319
Electroconvulsive Therapy
185
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
185
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Myasthenia Gravis: Diagnostic Tests
1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
446
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
446

